Expression Analysis, RainDance Offer Cancer Collaboration | GenomeWeb

NEW YORK (GenomeWeb News) – Expression Analysis and RainDance Technologies will collaborate to offer researchers services that can characterize rare genetic mutations relevant to complex diseases, particularly cancer, Expression Analysis said today.

The company said that the firms will work together with and sponsor eight researchers to "define a panel of high-priority genomic targets" that would be used in large-scale re-sequencing studies of cancer samples.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.